Contractions News and Research

RSS

Top-line primary endpoint data from Pfizer's Toviaz trial on overactive bladder

Pfizer Inc. announced today the top-line primary endpoint result for Toviaz (fesoterodine fumarate) Study A0221049 - Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder.

6 Dec 2011

The head plays key role in tiring endurance performances

Researchers from the University of Zurich have now studied in detail what sportsmen and women know from experience: The head plays a key role in tiring endurance performances.

5 Dec 2011

Dantrolene reduces severity of walking and balance problems linked with HD

Huntington's disease (HD) is characterized by ongoing destruction of specific neurons within the brain. It affects a person's ability to walk, talk, and think - leading to involuntary movement and loss of muscle co-ordination. New research published in BioMed Central's open access journal Molecular Neurodegeneration shows that the RyanR inhibitor Dantrolene is able to reduce the severity of walking and balance problems in a mouse model of HD.

24 Nov 2011

New device safe, more effective for patients with chronic neurological conditions

Functional electrical stimulation (FES) was developed to help return lost function to patients with upper and lower extremity injuries and spinal cord injuries, among other applications. However, the devices, which work by stimulating neuronal activity in nerve-damaged patients, have a potential shortcoming in that the electrical currents needed for the treatment to work can also send errant signals to surrounding nerves, resulting in painful side effects.

22 Nov 2011

Whole-body-vibration does not effectively boost bone density

Whole-body-vibration, a popular exercise which uses a vibrating platform, is sometimes advertised as being able to boost bone density. However, a one-year-study on healthy postmenopausal women has shown that it has no such effect.

15 Nov 2011

Pfizer's Toviaz Study A0221048 for overactive bladder meets primary endpoint

Pfizer Inc. announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 - Effectiveness and Safety of a Flexible Dose Regimen for Patients with Overactive Bladder including Nocturnal Urinary Urgency.

9 Nov 2011

Study reveals new role for the 'hormone of love'

Much of the body's chemistry is controlled by the brain - from blood pressure to appetite to food metabolism. In a study published recently in Developmental Cell, a team of scientists led by Dr. Gil Levkowitz of the Weizmann Institute has revealed the exact structure of one crucial brain area in which biochemical commands are passed from the brain cells to the bloodstream and from there to the body. In the process, they discovered a surprising new role for the 'hormone of love,' showing that it helps to direct the development of this brain structure.

3 Nov 2011

Researchers uncover molecular pathway critical to cardiac arrhythmia

University of Maryland School of Medicine researchers have uncovered a previously unknown molecular pathway that is critical to understanding cardiac arrhythmia and other heart muscle problems.

27 Oct 2011

Merz presents XEOMIN clinical data on dystonia at IDS 2011

New data presented at recent neurological congresses and summarized at the IDS indicate that patients treated with XEOMIN for cervical dystonia or blepharospasm (involuntary closing of the eyelids) experienced long-term sustained efficacy with a favorable safety profile in studies of up to 121 and 88 weeks duration, respectively.

22 Oct 2011

FSU biologists devise new way to watch how cells move

For better and for worse, human health depends on a cell's motility -- the ability to crawl from place to place. In every human body, millions of cells -are crawling around doing mostly good deeds --- though if any of those crawlers are cancerous, watch out.

19 Oct 2011

Levosimendan may effectively improve muscle function in patients with respiratory failure

Treatment with the calcium-sensitizing drug levosimendan may be effective in improving muscle function in patients with respiratory muscle weakness, which often accompanies chronic diseases such as chronic obstructive pulmonary disease (COPD) and congestive heart failure, according to researchers in the Netherlands, who studied the effects of the drug on healthy volunteers.

23 Sep 2011

Heart specialists reveal how pacemaker works at the biological level

Heart specialists at Johns Hopkins have figured out how a widely used pacemaker for heart failure, which makes both sides of the heart beat together to pump effectively, works at the biological level.

15 Sep 2011

Researchers describe new function of HCN channels in the heart

The heartbeat is the result of rhythmic contractions of the heart muscle, which are in turn regulated by electrical signals called action potentials. Action potentials result from the controlled flow of ions into heart muscle cells (depolarization) through channels in their membranes, and are followed by a compensating reverse ion current (repolarization), which restores the original state. If the duration of the repolarization phase is not just right, the risk of ventricular arrhythmia and sudden cardiac death increases significantly.

12 Sep 2011

Creighton pharmacology professor receives AAF's Early Excellence Award

Yaping Tu, Ph.D., associate professor of pharmacology at Creighton University School of Medicine, has received a $450,000 Early Excellence Award from the American Asthma Foundation.

31 Aug 2011

Plants stop lethal bleedings after birth in Tanzanian women

Researchers at the Faculty of Pharmaceutical Sciences, University of Copenhagen, have examined a number of plants which are used for illegal abortions in Tanzania. The lab tests show that several of the plants can make the uterus tissue contract and that the plants therefore can be used to stop lethal bleedings after birth. This new knowledge is now to be conveyed in rural Tanzania where access to medicine often is difficult.

26 Aug 2011

Allergan receives FDA approval for Botox to treat specific form of urinary incontinence

The U.S. Food and Drug Administration today approved Botox injection to treat urinary incontinence in people with neurologic conditions such as spinal cord injury and multiple sclerosis who have overactivity of the bladder.

25 Aug 2011

FDA approves Allergan's BOTOX to treat specific form of urinary incontinence

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX for injection for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition in adults who have an inadequate response to or are intolerant of an anticholinergic medication.

25 Aug 2011

Researchers demonstrate a way to control excitation and contraction in cardiac muscle cells

By employing optogenetics, a new field that uses genetically altered cells to respond to light, and a tandem unit cell (TCU) strategy, researchers at Stony Brook University have demonstrated a way to control cell excitation and contraction in cardiac muscle cells, the details of which are published in the early online edition of Circulation: Arrhythmia & Electrophysiology: "Stimulating Cardiac Muscle by Light: Cardiac Optogenetics by Cell Delivery."

19 Aug 2011

JAK protein triggers contractions in tumours and allows cancer cells to spread

Cancer Research UK-funded scientists have discovered that a protein called JAK triggers contractions in tumours which allows cancer cells to squeeze though tiny spaces and spread, in research published in Cancer Cell today.

17 Aug 2011

Allergan receives positive opinion from Irish Medicines Board for BOTOX

Allergan is pleased to announce that BOTOX has received a positive opinion from the Irish Medicines Board for the management of urinary incontinence in adults with neurogenic detrusor overactivity (NDO) resulting from neurogenic bladder due to stable sub-cervical spinal cord injury, or multiple sclerosis.

8 Aug 2011